Professor Jason Trubiano
National Allergy Centre of Excellence Drug Allergy Stream Co-chair
- Director of Infectious Diseases, Austin Health
- Head for the Centre for Antibiotic Allergy and Research, Austin Health
- NHMRC Emerging Leadership Fellow and Clinical Associate Professor, Department of Infectious Diseases, The University of Melbourne
Professor Jason Trubiano is an Infectious Diseases Physician and Director of Infectious Diseases. He is an NHMRC Emerging Leadership Fellow at Department of Infectious Diseases, The University of Melbourne and Cross Cutting Discipline Clinical Research Co-Lead at the Doherty Institute. He is the head for the Centre for Antibiotic Allergy and Research at Austin Health. The collaborative health services and translational research program focuses on drug hypersensitivity and antibiotic allergy. The Centre also hosts the National Antibiotic Allergy Network (NAAN) and Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR). NAAN is delivering a national Inpatient Penicillin Allergy Database, clinical and consumer protocols and antibiotic allergy advocacy and policy.
Prof Trubiano’s research explores health services programs for antibiotic allergy and novel diagnostics and pharmacogenomic predictors for severe T-cell mediated drug reactions. He leads clinical and translational studies at Austin Health and Peter MacCallum Cancer Centre investigating drug allergy and infections in the immunocompromised host. One of his current key projects is implementing point-of-care tools and precision medicine approaches for antibiotic allergy to improve prescribing and medication safety in health services.
RECENT PUBLICATIONS
The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR) - Providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions. World Allergy Organization Journal. Aug 2024
Validation of a digital self-assessment to identify low-risk penicillin and sulfa antibiotic allergies in adults (SELF-FAST). The Journal of Allergy and Clinical Immunology: In Practice. Aug 2024
Effectiveness of direct delabelling of allergy labels in type A adverse drug reactions to penicillin: a multicentre hospitalwide prospective cohort study. Journal of Antimicrobial Chemotherapy. Jul 2024
Oral challenge vs routine care to assess low-risk penicillin allergy in critically ill hospital patients (ORACLE): a pilot safety and feasibility randomised controlled trial. Intensive Care Medicine. May 2024
Durability of penicillin allergy delabeling and post-testing penicillin utilization in adults with immune compromise. The Journal of Allergy and Clinical Immunology: In Practice. Apr 2024
Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy. JAMA Internal Medicine. Jul 2023
Development and Validation of a Sulfa Antibiotic Allergy Clinical Decision Rule. JAMA Network. Jun 2023
The Who, What, When and Where of Inpatient Direct Oral Penicillin Challenge - Implications for health services implementation. Clinical Infectious Diseases. Mar 2023
Safety of COVID ‐19 vaccine challenge in patients with immediate adverse reactions to prior doses: A multi‐centre cohort study. Allergy. Aug 2022
Anaphylaxis in Victoria: presentations to emergency departments, with a focus on drug‐ and antimicrobial‐related cases. The Medical Journal of Australia. Mar 2022
Direct oral penicillin challenge for penicillin allergy delabeling as a health services intervention: A multicenter cohort study. Allergy. Nov 2021
Penicillin Allergy Delabeling Program: an exploratory economic evaluation in the Australian context. Internal Medicine Journal. Sept 2021
SELECTED STUDIES
KEY RESOURCES
Proudly in partnership with the National Allergy Council and allergy organisations
